Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study

by Davide Massimi, Brigida Barberio, Lorenzo Bertani, Francesco Costa, Antonio Ferronato, Sonia Facchin, Romilda Cardin, Linda Cingolani, Cesare Casadei, Renata D’Incà, Fabiana Zingone, Edoardo Vincenzo Savarino
Published 2021-06-01

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

by Linda Cingolani, Brigida Barberio, Fabiana Zingone, Antonio Ferronato, Lorenzo Bertani, Francesco Costa, Giorgia Bodini, Maria Giulia Demarzo, Piera Melatti, Alessandro Gubbiotti, Davide Massimi, Cesare Casadei, Renata D’Incà, Edoardo Vincenzo Savarino
Published 2021-05-01

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study

by Brigida Barberio, Linda Cingolani, Cristina Canova, Giulia Barbieri, Renato Sablich, Maria Teresa Urbano, Lorenzo Bertani, Francesco Costa, Giorgia Bodini, Maria Giulia Demarzo, Antonio Ferronato, Andrea Buda, Piera Melatti, Davide Massimi, Edoardo Vincenzo Savarino, Fabiana Zingone
Published 2021-07-01